bpc-157 randomized controlled trial humans 2025 for ACL recovery: hype vs. science | Adam C. Cady MHS, ATC, CSCS, PA-C posted on the topic What is BPC-157 and why

Description

Yoshida K, Korchynskyi O, Tak PP et al (2014) Citrullination of epithelial neutrophil-activating peptide 78/CXCL5 results in conversion from a non-monocyte-recruiting chemokine to a monocyte-recruiting chemokine

While it offers superior selectivity relative to charge-mediated strategies, its adoption requires a higher tolerance for complex RNA architectures and a less modular manufacturing workflow

CJC-1295 : A long-acting GHRH analog that boosts IGF-1 and GH, leading to improved body composition

Using the efficacy estimand in Novos 68-week Reimagine 2 trial, the highest 2.4-mg/2.4-mg dose of CagriSema was linked to a 1.91% reduction in HbA1c from a baseline of 8.2%, as compared to a roughly 0.1% drop among the placebo cohort and 1.75% reduction on the highest approved diabetes dose of Novos own Ozempic

At the end of the three-month study, both groups had a significant reduction in Leeds assessment of neuropathic symptoms and signs (LANSS) and Douleur Neuropathique (DN4) scores, but there was no significant difference between groups [39,40]